Actualités et Activités de Repertoire Immune Medicines
Dirigeants
Voir l'organigramme avec ses 17 principaux dirigeants
Biographies les plus recherchées chez Repertoire Immune Medicines
Changements de dirigeants chez Repertoire Immune Medicines
- Robert Andtbacka, a rejoint l'entreprise comme Chief Medical Officer (publié le 5 juin 2025).
Créer une alerte
pour suivre les mouvements de dirigeants chez Repertoire Immune Medicines.
Biotechnologie
Repertoire Immune Medicines a 2 350 concurrents dont Astellas Gene Therapies (Etats—Unis), Eurofins (Luxembourg) et Lonza (Suisse).
Actualités en fusion/acquisition en Biotechnologie.
- Eli Lilly has announced the acquisition of Verve Therapeutics (publié le 17 juin 2025).
- Sirius Therapeutics vient d'annoncer une levée de fonds de 50 millions de dollars. (publié le 16 juin 2025).
- BioNTech has announced the acquisition of CureVac (publié le 12 juin 2025).
Contacts en Biotechnologie
Actualités
Derniers communiqués de presse par Repertoire Immune Medicines
- Repertoire Immune Medicines Appoints Robert Andtbacka, MD, CM, FACS, FRCSC, as Chief Medical Officer and Advances TCR Bispecific Development Candidate Toward the Clinic • Repertoire Immune Medicines
- Repertoire® Immune Medicines Enters into Collaboration and License Agreement with Genentech for the Development of T cell-Targeted Therapies for an Autoimmune Disease • Repertoire Immune Medicines
- Repertoire® Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases • Repertoire Immune Medicines
- Repertoire® Immune Medicines Presents New Data From Its DECODE™ Platform Identifying Highly Prevalent Immunotherapeutic Targets in HPV-Positive Cancers, Unlocking Pathways for Potential Therapeutics • Repertoire Immune Medicines
- Torben Straight Nissen Joins Repertoire® Immune Medicines as Chief Executive Officer • Repertoire Immune Medicines
- New Data From Repertoire® Immune Medicines Demonstrate Effectiveness of Its DECODE™ Platform to Characterize and Identify New Immunotherapeutic Targets in HPV Positive Cancer • Repertoire Immune Medicines
- Repertoire® Immune Medicines Enters New Research Collaboration to Discover The T Cell Response to Therapy in HPV-Associated Cancers • Repertoire Immune Medicines
- Repertoire® Immune Medicines Identifies Novel Immune Targets in Pathogenesis of Type 1 Diabetes • Repertoire Immune Medicines
- Preclinical Research Published in SCIENCE ADVANCES Demonstrates Repertoire Immune Medicines’ Cell-tethering Technology Delivers Potent Interleukin-12 Directly to Solid Tumors Potentially Improving Effectiveness of Cellular Immunotherapies • Repertoire Imm
- https://s3.us-east-1.amazonaws.com/repertoire-assets.investeddigital.com/downloads/Repertoire-SITC-PRESS-RELEASE_FINAL_6-Nov-2020.pdf
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Repertoire Immune Medicines
- Repertoire Immune Medicines sur Wikipédia, Google News & Yahoo Finance en 1-click
- Repertoire Immune Medicines sur LinkedIn, Twitter & YouTube en 1-click
